Q2:16 Results Defy Brexit and Other Uncertainties

by | Jul 18, 2016 1:52 pm | eHealth, Medical Devices, Physician Medical Groups

You’ve seen the headlines: Global mergers and acquisitions slid in the first half of 2016, as did the combined value. The number of middle market deals completed in the second quarter fell to levels not seen since 2009. Buyers are walking away from targets that could be affected by sudden changes in tax regulations. It’s all thanks to Brexit and the U.S. presidential election. Then there’s the healthcare market. Deal volume actually increased compared with the previous quarter in 2016, and the same quarter a year ago. Deal volume for Q2:16 reached 396 announced transactions, up 11% versus Q1:16’s 358 deals, and 15% higher than last year’s 344 deals in the second quarter. For the first half... Read More »

Bravo to Healthcare Cyber-Security

by | Jul 14, 2016 7:47 pm | eHealth

Thoma Bravo, LLC, a leading private equity investment firm is certainly investing in the future with its latest acquisition of Imprivata® (NYSE: IMPR), a Massachusetts-based healthcare IT security company. Imprivata®’s technology enables healthcare organizations worldwide to access, communicate and transact patient information securely while also addressing critical compliance and security challenges. Thoma Bravo paid approximately $544 million for the company. As healthcare continues to go paperless, the need for strong and compliant security technology coupled with ease of access will only continue to grow. Read More »

Cells Sell…to GE At Least

by | Jul 13, 2016 6:51 pm | Biotechnology, Medical Devices

GE Healthcare, a subsidiary of GE (NYSE:GE), recently announced that it had acquired a privately-held Sweden-based company, Biosafe Group SA, a developer, manufacturer and supplier of products for cell processing in the areas of adult stem cell banking. The combined biological, engineering and industrial capabilities should advance cell therapy and cellular immunotherapy GE’s interest in cellular research is not new. In January 2016, GE Ventures completed a $31.5 million co-investment with the Canadian government to create the BridGE@CCRM Cell Therapy Centre of Excellence in order to promote new technologies for the product of new cellular therapies in Toronto. Then, in April, GE Ventures... Read More »